Drug Information

Drug General Information
Drug ID
D03FBV
Former ID
DNCL001779
Drug Name
PF-04950615
Drug Type
Antibody
Indication Hypercholesterolemia [ICD10:E78] Phase 3 [524502]
Company
Pfizer New York, NY
Target and Pathway
Target(s) Proprotein convertase subtilisin/kexin type 9 Target Info [532578]
WikiPathways PCSK9-mediated LDLR degradation
References
Ref 524502ClinicalTrials.gov (NCT01975376) The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. U.S. National Institutes of Health.
Ref 532578Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.